Elotuzumab Misses Mark Again as Frontline Treatment for Multiple Myeloma
Oncology/Hematology > > Myeloma-- No PFS take advantage of including the monoclonal antibody to basic treatment
by Charles Bankhead, Senior Editor, MedPage Today February 20, 2024
Elotuzumab (Empliciti) stopped working for a 3rd time to enhance progression-free survival (PFS) in recently detected several myeloma when contributed to basic treatment, a big randomized trial revealed.
After 4 years of follow-up, neither the average PFS nor the 3-year PFS varied considerably amongst 4 treatment groups who got lenalidomide (Revlimid) and bortezomib (Velcade) plus dexamethasone (RVd) with or without elotuzumab. The 3-year P...